الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 114 |  |  |
| | | from | 114 | | |
Abstract
PSTT achieves clinical results comparable to IVTA as regards the reduction in CMT and the improvement in VA although it achieves this effect somewhat slower and appears to act better on milder macular thicknesses. PSTT carries a lower rate of intraocular complications than IVTA injection and does not appear to affect the IOP, thus making it suitable for glaucomatous patients. The effect of PSTT decreases when the injection is associated with reflux of the drug through the buttonhole created for injection or to the anterior subtenon space.